Cargando…
Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
BACKGROUND: Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppressio...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885574/ https://www.ncbi.nlm.nih.gov/pubmed/31819511 http://dx.doi.org/10.2147/OTT.S223406 |
_version_ | 1783474757844336640 |
---|---|
author | Li, Guan-Zhang Zhang, Ke-Nan Wang, Zheng Hu, Hui-Min Wang, Zhi-Liang Huang, Ruo-Yu Jiang, Hao-Yu Zhai, You Feng, Yue-Mei Chang, Yuan-Hao Li, Ren-Peng Wu, Fan Zeng, Fan Jiang, Tao Zhang, Wei |
author_facet | Li, Guan-Zhang Zhang, Ke-Nan Wang, Zheng Hu, Hui-Min Wang, Zhi-Liang Huang, Ruo-Yu Jiang, Hao-Yu Zhai, You Feng, Yue-Mei Chang, Yuan-Hao Li, Ren-Peng Wu, Fan Zeng, Fan Jiang, Tao Zhang, Wei |
author_sort | Li, Guan-Zhang |
collection | PubMed |
description | BACKGROUND: Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppression. We aimed to study the characteristics and immune function of Siglec family members. METHODS: Transcriptome data from 1024 glioma samples and 1551 glioma single cells were used in our study. Clinical and molecular pathology information was also included. Statistical, bioinformatical methods, and single-cell sequencing analysis were applied to investigate the role of Siglec family members. RESULTS: Siglecs-5, −7, −9, and −16 showed a significant correlation with immunosuppression in glioma. They are typically expressed in higher grade, IDH-wildtype, and mesenchymal subtype gliomas. Siglec-5, −7, and −9 had a similar immune function to TIM-3, while Siglec-16 was similar to PD-L1, suppressing tumor immunity via different mechanisms. Joint use of Siglec-inhibitors and immune checkpoint inhibitors could prolong the survival of glioma patients. CONCLUSION: Siglec-5, −7, −9, and −16 suppressed tumor immunity in different ways. Joint usage of inhibitors may be an effective means to improve the efficacy of glioma immunotherapy. |
format | Online Article Text |
id | pubmed-6885574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68855742019-12-09 Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy Li, Guan-Zhang Zhang, Ke-Nan Wang, Zheng Hu, Hui-Min Wang, Zhi-Liang Huang, Ruo-Yu Jiang, Hao-Yu Zhai, You Feng, Yue-Mei Chang, Yuan-Hao Li, Ren-Peng Wu, Fan Zeng, Fan Jiang, Tao Zhang, Wei Onco Targets Ther Original Research BACKGROUND: Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppression. We aimed to study the characteristics and immune function of Siglec family members. METHODS: Transcriptome data from 1024 glioma samples and 1551 glioma single cells were used in our study. Clinical and molecular pathology information was also included. Statistical, bioinformatical methods, and single-cell sequencing analysis were applied to investigate the role of Siglec family members. RESULTS: Siglecs-5, −7, −9, and −16 showed a significant correlation with immunosuppression in glioma. They are typically expressed in higher grade, IDH-wildtype, and mesenchymal subtype gliomas. Siglec-5, −7, and −9 had a similar immune function to TIM-3, while Siglec-16 was similar to PD-L1, suppressing tumor immunity via different mechanisms. Joint use of Siglec-inhibitors and immune checkpoint inhibitors could prolong the survival of glioma patients. CONCLUSION: Siglec-5, −7, −9, and −16 suppressed tumor immunity in different ways. Joint usage of inhibitors may be an effective means to improve the efficacy of glioma immunotherapy. Dove 2019-11-27 /pmc/articles/PMC6885574/ /pubmed/31819511 http://dx.doi.org/10.2147/OTT.S223406 Text en © 2019 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Guan-Zhang Zhang, Ke-Nan Wang, Zheng Hu, Hui-Min Wang, Zhi-Liang Huang, Ruo-Yu Jiang, Hao-Yu Zhai, You Feng, Yue-Mei Chang, Yuan-Hao Li, Ren-Peng Wu, Fan Zeng, Fan Jiang, Tao Zhang, Wei Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title | Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title_full | Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title_fullStr | Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title_full_unstemmed | Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title_short | Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy |
title_sort | siglecs, novel immunotherapy targets, potentially enhance the effectiveness of existing immune checkpoint inhibitors in glioma immunotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885574/ https://www.ncbi.nlm.nih.gov/pubmed/31819511 http://dx.doi.org/10.2147/OTT.S223406 |
work_keys_str_mv | AT liguanzhang siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT zhangkenan siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT wangzheng siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT huhuimin siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT wangzhiliang siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT huangruoyu siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT jianghaoyu siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT zhaiyou siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT fengyuemei siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT changyuanhao siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT lirenpeng siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT wufan siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT zengfan siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT jiangtao siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy AT zhangwei siglecsnovelimmunotherapytargetspotentiallyenhancetheeffectivenessofexistingimmunecheckpointinhibitorsingliomaimmunotherapy |